### Tasks (Active Tasks: 14)

<table>
<thead>
<tr>
<th>Task</th>
<th>Task Type</th>
<th>Task Filter</th>
<th>Status</th>
<th>Order</th>
<th>Favorites</th>
<th>Notes</th>
<th>Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Primary Presenter</td>
<td>Authors</td>
<td></td>
<td>✔️</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2  Co-Author List</td>
<td>Co-Author List</td>
<td></td>
<td>✔️</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3  Abstract Submission Policies</td>
<td>Copyright/Permissions</td>
<td></td>
<td>✔️</td>
<td>2.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4  Abstract Details - Podium</td>
<td>Abstract</td>
<td>Podium Submission Only</td>
<td>✔️</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5  Abstract Details - Poster</td>
<td>Abstract</td>
<td>Poster Submission Only</td>
<td>✔️</td>
<td>3.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6  Abstract Details - Podium or Poster</td>
<td>Abstract</td>
<td>Either Podium or Poster Submission</td>
<td>✔️</td>
<td>3.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7  Abstract Details - Invited Speaker</td>
<td>Abstract</td>
<td>Invited Speaker</td>
<td>✔️</td>
<td>3.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8  Innovation Award</td>
<td>Award</td>
<td>Podium Submission Only</td>
<td>✔️</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9  Innovation Award - Invited Speaker</td>
<td>Award</td>
<td>Invited Speaker</td>
<td>✔️</td>
<td>4.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Innovation Award - Either Category</td>
<td>Award</td>
<td>Either Podium or Poster Submission</td>
<td>✔️</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Tony B. Academic Travel Award Application</td>
<td>Survey</td>
<td>Podium Submission Only</td>
<td>✔️</td>
<td>1000</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Title
A Randomized Controlled Trial of Nonalcoholic Steatohepatitis Therapy: Efficacy of Lifestyle Modification versus Pharmacotherapy versus Pharmacotherapy

197 characters (300 max)
21 words (75 max)

Abstract
Summarize the proposed research in 350 words or less.

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the US. As of 2008, up to a third of US adults had NAFLD, with an increased prevalence to greater than 90% in the population with obesity. Nonalcoholic steatohepatitis (NASH) is a spectrum of NAFLD that may progress to cirrhosis. To date, lifestyle modification to induce weight loss remains the mainstay therapy for NASH. Traditionally, weight loss therapies include lifestyle modification, pharmacotherapy and bariatric surgery. However, endoscopic bariatric therapy, such as an intragastric balloon (IGB), has recently been developed to bridge the gap between lifestyle modification/pharmacotherapy and bariatric surgery. This project is designed to compare pharmacotherapy plus an applicator of endoscopic bariatric with IGB.

347 words (350 max)

Funds Requested
(no more than $15,000)

$15,000
1 words (4 max)
INNOVATION AWARD - EITHER CATEGORY

Please indicate your interest in this award or opt-out by clicking on the 'Skip' button. Complete details about the award can be found at http://www.slas.org/awards/innovationAward.cfm

SLAS Innovation Award
Please check the box below to indicate if you wish for your abstract (if chosen) to be considered for the SLAS $10,000 Innovation Award.
Complete details about the award can be found at http://www.slas.org/awards/innovationAward.cfm

I am interested in being considered for the SLAS Innovation Award.

  ○ Yes  ○ No

Submit Information  Skip
Conference Harvester
EXHIBITOR HARVESTER

SELECT & RENT BOOTHs

SEARCH FILTER

Booth Selection

Please select the available booth that you would like to rent. Each 10' x 10' booth receives three (3) complimentary Exhibitor badges. Additional Exhibitor badges may be purchased for $135.

Please select a booth from the list below...

Note: You can also click on the booths in the floor plan below to see which companies have already rented booths and the details for each available booth.

Booth 10: 10 x 10 — $3,200
Booth 16: 10 x 10 — $3,200
Booth 17: 10 x 10 — $3,300
Booth 19: 10 x 10 — $3,500 ($3,300 + Corner Fee: $200)
Booth 112: 10 x 10 — $3,300
Booth 128: 10 x 10 — $3,300
Booth 129: 10 x 10 — $3,300
Booth 130: 10 x 10 — $3,300
Booth 131: 10 x 10 — $3,300
Booth 132: 10 x 10 — $3,300
Booth 133: 10 x 10 — $3,500 ($3,300 + Corner Fee: $200)
Booth 134: 10 x 10 — $3,300
Booth 136: 10 x 10 — $3,300
Booth 138: 10 x 10 — $3,300
Booth 140: 10 x 10 — $3,300

MacBook Air
Survey of Adult Technology Skills

Distribution of Computer Skills Among People Aged 66-85
AN ONSITE APP FOR MEETING PLANNERS!

CREATE TO-DOS

SEND ALERTS

eventScribe®
BOOST - MOBILE APP
eventScribe®
BOOST - MOBILE APP

AN ONSITE APP FOR MEETING PLANNERS!

CONTACT YOUR TEAM

CREATE TASKS, CONTACT YOUR TEAM, SEND ALERTS, AND VIEW APP STATISTICS
MATCHING AMPLIFICATION TARGETS IN THE DAY OF FITTING FOR NEW HEARING AID USERS

- **Graphs:**
  - Graph 1: Comparison of different variables over time.
  - Graph 2: Distribution of data points.

- **Tables:**
  - Table 1: Comparison of parameters across different conditions.

- **Text Content:**
  - Description of experimental methods and results.

- **References:**
  - List of cited sources and further reading materials.

**Keywords:**
- Amplification
- Matching
- Target
- Day of Fitting
- New Hearing Aids

**Authors:**
- [Author Names]

**Institution:**
- [Institution Name]
(129) Development of a Cell-based RSV Virus Infection High Throughput Screening Assay Utilizing Primary Human Small Airway Epithelial Cells (hSAEC)

Jeff Gobel, BS Chem/BS Engineering – Senior Scientist, GlaxoSmithKline

Respiratory syncytial virus (RSV) is a commonly occurring pathogen that can cause severe disease in children, the elderly and immunocompromised individuals. The economic impact of RSV infections exceeds $1 Billion annually in hospitalizations and indirect medical costs. At present, the only approved therapy is a prophylactic monoclonal antibody which is extremely costly and reserved for use in high risk infants and children. Hence, there is a large, unmet clinical need for RSV medications.

Collaboration between the screening, assay development, and disease focused groups successfully yielded a high-throughput, primary cell-based antiviral assay to enable identification of small molecules with antiviral protection against RSV using cytopathic effect (CPE) as a phenotypic endpoint. In order to provide increased biological relevance, we developed our assay with primary human small airway epithelial cells (hSAEC) which originate from known alveolar RSV infection and replication instead of a more traditional immortalized cell line. Using purchased low passage cells, cost effective large scale culture methods were developed to provide assay-ready frozen hSAEC. The RSV virus was amplified in-house. Following a 6 day incubation period with virus, cell viability is measured after addition of a commercially available reagent, CellTiter-Glo™, which provides luminescent detection of ATP, an indicator of metabolically active cells. Compounds with antiviral activity protect SAEC from cytopathic effects induced by RSV viral infection and replication.

Your Notes
A really interesting study on Single Shot Assay performance. 0.5-0.6 is by far the highest Plate Count - surprising! Successful creation of a scale-up protocol that generated sufficient primary cells to complete a high quality HTS campaign. Robust Assays have a 1.19% hit rate

(145) Mix-and-Read Assays for High-throughput Imaging

Jayne Hasley – Applications Scientist, Molecular Devices, LLC

Colorimetric and fluorescent assays have long been used for screening for select antibodies in solution. However, these assays can involve...
SELECT SESSIONS ATTENDED & COMPLETE EVALUATION

![Green checkmark]

Task completed
This task is complete, but you can continue to update the data.

Select the sessions you attended. This will affect the total number of credits that will print on your certificate and you will only see the questions applicable to the sessions you attended.

Once you have completed all of your session evaluations, select the “Back to Task List” button above to access your certificate.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Presentation</th>
<th>Select Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/19/2016</td>
<td>9:00 AM - 12:00 PM</td>
<td>ETAU Introduction to Electronic Processing</td>
<td></td>
</tr>
<tr>
<td>4/19/2016</td>
<td>9:00 AM - 9:50 AM</td>
<td>What Beacons Bring to the Consumer Experience</td>
<td>1.00</td>
</tr>
<tr>
<td>4/19/2016</td>
<td>9:00 AM - 9:50 AM</td>
<td>From the Hill to the Rose Garden: Washington, the Payments Industry and a Few Thorny Issues</td>
<td>1.00</td>
</tr>
<tr>
<td>4/19/2016</td>
<td>9:00 AM - 9:50 AM</td>
<td>Enhancing Global Sales in a Seamless Marketplace</td>
<td>1.00</td>
</tr>
<tr>
<td>4/19/2016</td>
<td>9:00 AM - 9:50 AM</td>
<td>Beyond EMV: P2PE and Tokenization for Security Best Practices</td>
<td>1.00</td>
</tr>
<tr>
<td>4/19/2016</td>
<td>9:00 AM - 9:50 AM</td>
<td>Bringing Digital Payments to the Omni-Channel Shopper</td>
<td>1.00</td>
</tr>
</tbody>
</table>
Total Responses: 106
Most recent response: 11/1/2016 12:29:09 PM

1. How many events/trade shows does your company participate in annually?

2. Other (Please Specify):

3. Rate your overall event experience:

4. My objectives for attending were met?

5. Please explain why you chose Yes or No:

<table>
<thead>
<tr>
<th>QUESTION TYPE</th>
<th>TOTAL RESPONSES</th>
<th>AVG. RESPONSE TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long Response</td>
<td>49</td>
<td>n/a</td>
</tr>
</tbody>
</table>

1) Able to attend break-out sessions that discussed BI solutions.

2) I learned a lot especially in the academy.

3) Not as much content as I remember. Also too much down time between sessions.
TRANSACT: Powered by ETA

CERTIFICATE OF ATTENDANCE FOR
Scott Anderson

Sessions Attended (Credits):
- Shift Happens (1)
- The FiTech Race: How Financial Services Companies Can Compete with Silicon Valley (1)
- There's an App for That: How Apps Are Transforming Businesses (1)
- Leveraging Technology to Build Merchant Loyalty (1)
- Millennials: How They're Shaping the Future of Payments (1)
- Take a Bigger Bite of the Payments Pie (1)
- The Future of Financial Services (0.5)
- Industry IPOs: What Will They Mean to the Industry? (1)

Total ETA CPP CE Credits: 7.5

[Signature]

Verified by ETA
Client Panel: How Planners Have Used the CadmiumCD Platform

Welcome CadmiumCD clients and users who have used the CadmiumCD platform in unique, innovative, or extraordinary ways to plan, manage and deliver exceptional educational experiences to their attendees. The panel will include 4 CadmiumCD users from various fields, backgrounds, and use-cases.

Panelist(s):
- Alicia "Alise" Navarro
  Meeting Coordinator
  American Library Association
- Michele James
  Project Assistant
  Mayo Clinic
- Bottom Panel

475 Views
## Agenda

### Wednesday, July 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM - 9:50 AM</td>
<td>Workshops</td>
</tr>
<tr>
<td>10:00 AM - 10:50 AM</td>
<td>Workshops</td>
</tr>
<tr>
<td>11:00 AM - 11:50 AM</td>
<td>Workshops</td>
</tr>
</tbody>
</table>

- **eventScribe Back to Basics 301 - Mobile App Launch Tips**
- **eventScribe App**
- **Harvester Back to Basics 301 - Worksheets & Presentations**
- **Conference Harvester**
- **Scorecard Back to Basics 301 - Emails, Worksheets, Reports, and**